Effects of vaccinium arctostaphylos fruit on cardiometabolic indices in hypertensive obese patients

Clinical trial comparing the effects of Vaccinium arctostaphylos fruit extract with placebo on the blood levels of glycosylated hemoglobin and LDL-choletserol, amounts of systolic and diastolic blood pressures, body mass index and waist circumference in hypertensive obese patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201710302288N12

Enrollment

100

Registered

2017-11-15

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Obesity. Condition 2: Hypertension. Obesity due to excess calories Essential (primary) hypertension

Interventions

Intervention 1: Vaccinium arctostaphylos fruit extract is administered at the dose of one 400 mg capsule every 8 hours to a group of 50 patients for 3 months. Intervention 2: One placebo capsule is a

Treatment - Drugs

Placebo

Vaccinium arctostaphylos fruit extract is administered at the dose of one 400 mg capsule every 8 hours to a group of 50 patients for 3 months

One placebo capsule is adminstered every 8 hours to a group of 50 patients for 3 months

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Iranian male and female hypertensive obese outpatients; patients aged 30 to 80 years; patients with body mass index between 25 kilograms per square meter and 35 kilograms per square meter; patients with systolic blood pressures between 14 and 16 mmHg; patients with diastolic blood pressures between 8 and 10 mmHg; patients taking synthetic antihypertensive drugs with 2 different mechanisms. Exclusion criteria: Patients taking other drugs effective on the blood glucose and lipid levels and body weight; patients with cardiac, renal, hepatic, hematological diseases, hypothyroidism, tachycardia, vertigo and seizure; patients with a history of gallstones or gall bladder surgery; pregnant women; women planning pregnancy; breast-feeding women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood level of glycosylated hemoglobin. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood level of low density lipoprotein cholesterol. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Body mass index. Timepoint: Before and after 3 months of intervention. Method of measurement: Scale and tape measure.;Waist circumference. Timepoint: Before and after 3 months of intervention. Method of measurement: Tape measure.;Systolic blood pressure. Timepoint: Before and after 3 months of intervention. Method of measurement: 24-hour ambulatory blood pressure monitoring.;Diastolic blood pressure. Timepoint: Before and after 3 months of intervention. Method of measurement: 24-hour ambulatory blood pressure monitoring.	—

Measure

Time frame

Blood level of glycosylated hemoglobin. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood level of low density lipoprotein cholesterol. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Body mass index. Timepoint: Before and after 3 months of intervention. Method of measurement: Scale and tape measure.;Waist circumference. Timepoint: Before and after 3 months of intervention. Method of measurement: Tape measure.;Systolic blood pressure. Timepoint: Before and after 3 months of intervention. Method of measurement: 24-hour ambulatory blood pressure monitoring.;Diastolic blood pressure. Timepoint: Before and after 3 months of intervention. Method of measurement: 24-hour ambulatory blood pressure monitoring.

—

Secondary

Measure	Time frame
Fasting blood glucose level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood total choletserol level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood triglyceride level. Timepoint: Before and after 3 months of intervention. Method of measurement: kit.;Blood high density lipoprotein cholesterlol level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood serum glutamate oxaloacetate transaminase level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood serum glutatamate pyruvate transaminase level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood creatinine level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.	—

Measure

Time frame

Fasting blood glucose level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood total choletserol level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood triglyceride level. Timepoint: Before and after 3 months of intervention. Method of measurement: kit.;Blood high density lipoprotein cholesterlol level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood serum glutamate oxaloacetate transaminase level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood serum glutatamate pyruvate transaminase level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.;Blood creatinine level. Timepoint: Before and after 3 months of intervention. Method of measurement: Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Saeed Kianbakht

ACECR Institute of Medicinal Plants

skianbakht@yahoo.com; kianbakht@imp.ac.ir+98 26 3476 4010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026